Controlling angiogenesis with anti-VEGF therapy, which is now the standard treatment modality for wet AMD patients, prevents further macular damage by inhibiting the growth of new vessels and thus stabilizes vision. This evidence concerns the gene VEGFA and wet macular degeneration.